Physician profile
Ruston Jennings
NPI 1972532323
$8,838.31
in general payments reported to CMS, 2019-2025
57 companies · $994 in 2025
The $994 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,517 · 2020: $1,297 · 2021: $1,471 · 2022: $1,350 · 2023: $1,240 · 2024: $969 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,184 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,184.10 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $724.47 | 2019-2022 | |
| Abbvie INC. | $712.62 | 2019-2025 | |
| Novo Nordisk INC | $633.44 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $631.57 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $551.73 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $456.79 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $410.99 | 2019-2023 | Belsomra, Dificid, Steglatro |
| Pfizer INC. | $337.63 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $325.22 | 2019-2024 | |
| Abbott Laboratories | $296.44 | 2021-2024 | Freestyle Libre 3, Proclaim |
| Astellas Pharma US INC | $290.85 | 2019-2022 | |
| Allergan, INC. | $262.85 | 2019-2020 | |
| Exact Sciences Corporation | $260.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $253.46 | 2019-2025 | Relistor, Xifaxan |
| Glaxosmithkline, LLC. | $234.18 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruston Jennings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.